Ashley Jiayi Zhou
ABSTRACT
Uterine cancer is the 4th most common cancer among women, with about 66,570 new cases in the United States every year. Late-stage uterine cancer patients have a less than 20% chance of survival due to limited effectiveness in treatment options. Immunotherapy is an emerging type of cancer treatment; however, it is only effective in a subtype of uterine cancer (∼20%). Major histocompatibility complex I (MHC-I) molecules have been researched as a main mechanism assisting cancerous cells to evade death by immune cell destruction. The goal of this project is to identify molecular regulators of MHC-I in uterine cancer to aid immunotherapy. Here, we analyzed the prognostic value of MHC-I molecules based on patient and molecular datasets from The Cancer Genome Atlas. MHC-I combined with T cell markers is associated with better prognosis in uterine cancer. Two molecular candidates, interferon regulatory factor 1 (IRF1) and proteasome subunit beta type-9 (PSMB9), were identified as potential MHC-I regulators. Wet-lab experiments confirmed the role of IRF1 in regulating MHC-I expression, though PSMB9 was found to be ineffective. Furthermore, uterine cancer expressed lower levels of IRF1 compared with normal uterine tissues. This finding brings significant insight into a potential immunotherapy target molecule for treating uterine cancer. Future development includes direct testing of T cell immune responses with IRF1 enhancements to prove its effectiveness on immune cell action.
- American Cancer Society, Key Statistics for Endometrial Cancer, https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html.Google Scholar
- B.A. Dyer, C.H. Feng, R. Eskander, A.B. Sharabi, L.K. Mell, M. McHale, J.S. Mayadev, Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined with Radiation, Int J Radiat Oncol Biol Phys, 109 (2021) 396-412.Google ScholarCross Ref
- U.P. Hegde, B. Mukherji, Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies, Cancer Immunol Immunother, 66 (2017) 1113-1121.Google ScholarCross Ref
- T. Okuda, A. Sekizawa, Y. Purwosunu, M. Nagatsuka, M. Morioka, M. Hayashi, T. Okai, Genetics of endometrial cancers, Obstet Gynecol Int, 2010 (2010) 984013.Google ScholarCross Ref
- K. Natarajan, H. Li, R.A. Mariuzza, D.H. Margulies, MHC class I molecules, structure and function, Rev Immunogenet, 1 (1999) 32-46.Google Scholar
- J. Bubenik, Tumour MHC class I downregulation and immunotherapy (Review), Oncol Rep, 10 (2003) 2005-2008.Google Scholar
- A.M. Cornel, I.L. Mimpen, S. Nierkens, MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy, Cancers (Basel), 12 (2020).Google Scholar
- Lin, G., Chai, J., Yuan, S., Mai, C., Cai, L., Murphy, R. W., Zhou, W., & Luo, J. (2016). VennPainter: A Tool for the Comparison and Identification of Candidate Genes Based on Venn Diagrams. PloS one, 11(4), e0154315.Google Scholar
- Jorgovanovic, D., Song, M., Wang, L. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res 8, 49 (2020).Google ScholarCross Ref
- Xia, Y., Shen, S., & Verma, I. M. (2014). NF-κB, an active player in human cancers. Cancer immunology research, 2(9), 823–830.Google Scholar
- F. Dominguez, C. Simon, A. Quinonero, M.A. Ramirez, E. Gonzalez-Munoz, H. Burghardt, A. Cervero, S. Martinez, A. Pellicer, M. Palacin, F. Sanchez-Madrid, M. Yanez-Mo, Human endometrial CD98 is essential for blastocyst adhesion, PLoS One, 5 (2010) e13380.Google ScholarCross Ref
- P. Kralik, M. Ricchi, A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions, Parameters, and Everything, Front Microbiol, 8 (2017) 108.Google ScholarCross Ref
- H. Jiao, L. Zeng, S. Yang, J. Zhang, W. Lou, Knockdown EIF3C Suppresses Cell Proliferation and Increases Apoptosis in Pancreatic Cancer Cell, Dose Response, 18 (2020) 1559325820950061.Google ScholarCross Ref
- Q.F. Wu, C. Liu, M.H. Tai, D. Liu, L. Lei, R.T. Wang, M. Tian, Y. Lu, Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro, Acta Pharmacol Sin, 31 (2010) 361-366.Google ScholarCross Ref
- Wai Chung Chen, Tuo Hu, Chunbo He. The immune cell infiltration and landscape predicts clinical outcomes in gynecologic cancers [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2020 Oct 19-20. Philadelphia (PA): AACR; Cancer Immunol Res 2021;9(2 Suppl): Abstract nr PO067.Google Scholar
- S. Matikainen, T. Ronni, M. Hurme, R. Pine, I. Julkunen, Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells, Blood, 88 (1996) 114-123.Google ScholarCross Ref
Index Terms
- Restoring MHC-I Molecules to Potentiate Immunotherapy in Uterine Cancer
Recommendations
STAT1 Regulates the Expression of MHC-I Class Molecules in Ovarian Cancer
ICBIP '22: Proceedings of the 7th International Conference on Biomedical Signal and Image ProcessingSignificant advances have been made in cancer immunotherapy in recent years. However, few patients with ovarian cancer have benefited from immunotherapy and the prognosis is usually poor. A major mechanism by which cancer is rarely detected by immune ...
Overview of Cancer Immunotherapy
ICBBE '20: Proceedings of the 2020 7th International Conference on Biomedical and Bioinformatics EngineeringCancer is known as malignant tumor, with a high fatality rate. Early treatment include resection, radiation therapy and chemotherapy, however, due to the severe injure to human, immunotherapy has been proposed. Immune checkpoints are one of the major ...
Analysis of the Correlation between Immunogenomic Phenotype and Patient Outcomes in Prostate Cancer
ICBBT '22: Proceedings of the 14th International Conference on Bioinformatics and Biomedical TechnologyAlthough early-stage prostate cancer remains a good response to standard therapies, there are few treatment options for advanced stages or recurrent prostate cancer. Immunotherapy is currently the standard treatment for many types of cancers. However, ...
Comments